Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
83 hedge funds and large institutions have $158M invested in Kezar Life Sciences in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
29% more capital invested
Capital invested by funds: $123M → $158M (+$35.1M)
8% more funds holding
Funds holding: 77 → 83 (+6)
0.45% more ownership
Funds ownership: 5.09% → 5.53% (+0.45%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
83% less call options, than puts
Call options by funds: $14K | Put options by funds: $84K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$11.1M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.68M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$4.39M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.37M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$631K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.03M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.17M |
| 3 |
Millennium Management
New York
|
-$853K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$337K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$252K |
KZR Hedge Fund Activity: Q1 2021 in Review
83 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2021, worth a combined $158M — up 29% from $123M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new KZR positions and 6 closed out — a net gain of 6 holders — while 23 added to existing stakes and 31 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $11.1M. The largest seller was Fidelity Investments, cutting an estimated $3.03M.
- 83 institutional investors held Kezar Life Sciences (KZR) as of Q1 2021, up from 77 in Q4 2020.
- Funds reported $158M of Kezar Life Sciences stock for Q1 2021, up 29% quarter-over-quarter.
- 12 funds opened new Kezar Life Sciences positions in Q1 2021 and 6 closed out, a net change of +6 holders.
- The largest Kezar Life Sciences buyer in Q1 2021 was Avidity Partners Management, an estimated $11.1M added.
- The largest Kezar Life Sciences seller in Q1 2021 was Fidelity Investments, an estimated $3.03M sold.
Based on aggregated 13F filings for Q1 2021.